Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride is more effective than finasteride for hair regrowth in male and female pattern hair loss, with similar side effects.

Spironolactone does not increase the risk of breast cancer recurrence.

Some treatments like intralesional steroids and 5α-reductase inhibitors are effective for frontal fibrosing alopecia, but more research is needed.

Male baldness is not significantly associated with coronary artery disease.

H-1 antihistamines may help with various skin conditions, but more research is needed to confirm their effectiveness.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

Women with PCOS are more than twice as likely to develop nonalcoholic fatty liver disease.

High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.

People with lichen planus are more likely to have dyslipidemia, especially higher triglyceride levels.

The machine learning model accurately predicts Systemic Lupus Erythematosus in Omani patients.

Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.

The analysis found that alopecia areata, a hair loss condition, is not very common in Australia, affecting about 0.13% of people, with new cases most often seen in males aged 19 to 34 years.

Patients with long COVID after Omicron had fewer hospitalizations and milder symptoms but more fatigue, insomnia, and cough compared to those with Delta.

Some medications might reverse gray hair, especially those that reduce inflammation or stimulate pigment production, and vitamin B might help.

Finasteride improves hair growth and reduces hirsutism in women, but side effects and optimal dosages need further research.

The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.

COVID-19 leaves 80% of patients with long-term symptoms like fatigue and headaches.

Low-level laser therapy may improve hair regrowth and thickness for androgenetic alopecia, but more research is needed.

Kidney transplant patients who had COVID-19 experienced a significant drop in their quality of life due to long-lasting symptoms.

Multimodal recruitment effectively gathered a diverse group for an online survey on ovulation and menstruation health.

People with Major Depressive Disorder have a higher chance of getting Alopecia Areata, and vice versa; antidepressants may lower this risk.

Fat tissue treatments may help with wound healing and hair growth, but more research with larger groups is needed to be sure.

One-third of COVID-19 patients had long-term symptoms like hair loss and fatigue, with women, older individuals, blood group B, smokers, and those with more virus exposure at higher risk.

Low-level laser therapy can improve hair density in people with androgenic alopecia, but more research is needed to find out who it works best for.

Using 5-alpha reductase inhibitors may increase the risk of mild depression.

People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.

Some alternative treatments for hair loss might work, but more research is needed.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Topical JAK inhibitors may help treat some skin conditions but need more research.

Hormone treatment for transgender patients may not need to be stopped before surgery, but more research is needed, especially on estrogen.